EMD Serono, the healthcare business of Merck KGaA, and The University of Texas MD Anderson Cancer Center, have entered a three-year strategic collaboration to advance the development of cancer therapies for breast, colorectal, glioblastoma cancers and leukemia. EMD Serono will gain access to the Adaptive Patient-Oriented Longitudinal Learning and Optimization Platform (APOLLO) – MD Anderson’s research platform that standardizes the long-term collection of patients’ medical history...